90% of Hospital Providers Lost Revenue Due to Inefficient Data Use 98% openly acknowledged that their provider organization must improve the way it leverages data to confront challenges CHICAGO–(BUSINESS WIRE)–Intelligent Medical Objects (IMO), a healthcare data enablement company, conducted a survey of more than 300 provider leaders who are responsible for implementing and purchasing technology … [Read more…]

– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – REZZAYO is the first new FDA-approved echinocandin in over a decade – SAN DIEGO & PARSIPPANY, N.J.–(BUSINESS WIRE)–Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today … [Read more…]

SEATTLE–(BUSINESS WIRE)–Morphimmune, Inc., a preclinical biotechnology company focused on developing targeted oncology therapeutics, today announced the appointment of Clay Siegall, Ph.D. as its CEO and President. “Clay is a highly passionate and effective leader with a demonstrated ability to build significant value for an emerging biotechnology company,” said Isaac Barchas, Morphimmune’s Founding Board Chairman, co-founder … [Read more…]

A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter … [Read more…]

Strategically Focused Company Structure to Prioritize Clinical Development and Deliver Critical, Clinical-Stage Data SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 Phase 1 SQZ-AAC-HPV-101 Clinical Trial to Continue Following the Recent Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–Cerebral palsy is the most common childhood physical disability in the United States and throughout the world. To educate both professionals and family members engaged with the disorder, a whole-day event will be held by the Center for Cerebral Palsy on March 25 at the UCLA/Luskin Orthopaedic Institute for Children in Los Angeles. … [Read more…]

GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of Directors, effective April 1, 2023. The company also announced that Kristen Miranda, who has served as a director since March 2021, will retire as … [Read more…]

LARGO, Fla.–(BUSINESS WIRE)–CONMED Corporation (NYSE: CNMD) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 24, 2023, at 1:30 p.m. ET at its corporate headquarters at 11311 Concept Boulevard, Largo FL and through the internet virtually. Shareholders of record at the close of business on March 28, 2023 shall be … [Read more…]

CHICAGO–(BUSINESS WIRE)–#healthIT–Veradigm Inc. (NASDAQ: MDRX), announced today an update on the status of its year-end audit procedures for 2022. As the Company disclosed on February 28, 2023, due to an expansion of year-end audit procedures, the Company filed with the SEC a Form 12b-25, extending the due date of its annual report on Form 10-K … [Read more…]

Topline Phase 3 data for presbyopia candidate anticipated in Q2, 2023 SEATTLE & IRVINE, Calif.–(BUSINESS WIRE)–#VisusTx–Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced it has completed patient enrollment and the last visit has been conducted in BRIO-I, a pivotal … [Read more…]